Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial

IMPORTANCE: The benefit of neoadjuvant camrelizumab plus chemotherapy for resectable stage IIIA or IIIB non–small cell lung cancer (NSCLC) remains unknown. OBJECTIVE: To assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy vs chemotherapy alone for patients with resectable st...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jie, Zhao, Jinbo, Gong, Li, Ni, Yunfeng, Zhou, Yongan, Tian, Feng, Liu, Honggang, Gu, Zhongping, Huang, Lijun, Lu, Qiang, Wang, Xiaoping, Sun, Jianyong, Yang, Ende, Wang, Tao, Zhong, Daixing, Wang, Jian, Zhao, Zhengwei, Liu, Zhigang, Wang, Cheng, Wang, Xiaojing, Lei, Guangyan, Yan, Xiaolong, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401395/
https://www.ncbi.nlm.nih.gov/pubmed/37535377
http://dx.doi.org/10.1001/jamaoncol.2023.2751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401395/
https://www.ncbi.nlm.nih.gov/pubmed/37535377
http://dx.doi.org/10.1001/jamaoncol.2023.2751

Ejemplares similares